This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Jan 1;29(suppl_1):i1-i2.

doi: 10.1093/annonc/mdx724.

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years

J Vansteenkiste¹, E Wauters¹

Affiliations

PMID: 29462258
DOI: 10.1093/annonc/mdx724

Free article

Editorial

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years

J Vansteenkiste et al. Ann Oncol. 2018.

Free article

. 2018 Jan 1;29(suppl_1):i1-i2.

doi: 10.1093/annonc/mdx724.

Authors

J Vansteenkiste¹, E Wauters¹

Affiliation

¹ Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospitals KU Leuven, Leuven, Belgium.

PMID: 29462258
DOI: 10.1093/annonc/mdx724

No abstract available

PubMed Disclaimer

Similar articles

NSCLC drug targets acquire new visibility.
Friedrich MJ. Friedrich MJ. J Natl Cancer Inst. 2011 Mar 2;103(5):366-7. doi: 10.1093/jnci/djr056. Epub 2011 Feb 25. J Natl Cancer Inst. 2011. PMID: 21357596 No abstract available.
Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.
Schueler J, Tschuch C, Klingner K, Bug D, Peille AL, de Koning L, Oswald E, Klett H, Sommergruber W. Schueler J, et al. Cells. 2019 Jul 18;8(7):740. doi: 10.3390/cells8070740. Cells. 2019. PMID: 31323891 Free PMC article.
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Desai S, Kim C, Veytsman I. Desai S, et al. Curr Oncol Rep. 2019 Aug 13;21(9):84. doi: 10.1007/s11912-019-0835-x. Curr Oncol Rep. 2019. PMID: 31410582 Review.
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Saijo N. Saijo N. Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168. Nat Rev Clin Oncol. 2010. PMID: 20981125 No abstract available.
[Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
Zhang H, Zhang S. Zhang H, et al. Zhongguo Fei Ai Za Zhi. 2017 Jan 20;20(1):61-65. doi: 10.3779/j.issn.1009-3419.2017.01.09. Zhongguo Fei Ai Za Zhi. 2017. PMID: 28103975 Free PMC article. Review. Chinese.

See all similar articles

Cited by

Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature review.
Marampon F, Gelibter AJ, Cicco PR, Parisi M, Serpone M, De Felice F, Bulzonetti N, Musio D, Cortesi E, Tombolini V. Marampon F, et al. BJR Case Rep. 2022 Sep 12;8(5):20200134. doi: 10.1259/bjrcr.20200134. eCollection 2022 Sep 12. BJR Case Rep. 2022. PMID: 36211614 Free PMC article.
Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment.
Kapoor SS, Zaiss DMW. Kapoor SS, et al. Biomedicines. 2021 Dec 27;10(1):52. doi: 10.3390/biomedicines10010052. Biomedicines. 2021. PMID: 35052732 Free PMC article. Review.
The importance of protein domain mutations in cancer therapy.
Chitluri KK, Emerson IA. Chitluri KK, et al. Heliyon. 2024 Mar 9;10(6):e27655. doi: 10.1016/j.heliyon.2024.e27655. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38509890 Free PMC article. Review.
Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.
Liu Y, Dai X, Jiang S, Qahar M, Feng C, Guo D, Wang L, Ma S, Huang L. Liu Y, et al. Int J Mol Sci. 2022 Jul 21;23(14):8025. doi: 10.3390/ijms23148025. Int J Mol Sci. 2022. PMID: 35887373 Free PMC article.
Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.
Yoshimatsu Y, Ebi N, Ooi R, Sueyasu T, Nishizawa S, Munechika M, Yoshimine K, Ko Y, Ide H, Tsuruno K, Tobino K. Yoshimatsu Y, et al. Intern Med. 2021 Apr 1;60(7):1067-1071. doi: 10.2169/internalmedicine.5463-20. Epub 2020 Nov 2. Intern Med. 2021. PMID: 33132329 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal